diminazene DAO | 145855-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diminazene DAO
• 英文别名: diminazene diamidoxime
• CAS: 145855-63-6
• 化学式: C₁₄H₁₅N₇O₂
• 分子量: 313.319
• InChiKey: CVJALUVRVNVEGD-UHFFFAOYSA-N

物化性质

• 沸点：
  512.3±60.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  153.97
• 氢给体数：
  5.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  diminazene DAO 在 cytochrome b5 、 mitochondrial amidoxime reducing component 1 、 NADH cytochrome b5 reductase 、 还原型辅酶Ⅰ 作用下， 生成 diminazene monoamidoxime
  参考文献：
  名称：

  The Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the Activation of N-Hydroxylated Prodrugs

  摘要：

  The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b(5) and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.

  DOI：

  10.1021/jm8010417

文献信息

• Clement; Immel; Raether, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 12, p. 1497 - 1504
  作者：Clement、Immel、Raether

  DOI：——

  日期：——
• METHOD FOR PRODUCING PRODRUG FROM AMIDOXIME AND N-HYDROXYGUANIDINE CARBOXYLIC ACID ESTERS
  申请人：Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG

  公开号：US20140350293A1

  公开（公告）日：2014-11-27

  The invention relates to a method for improving the bioavailability of pharmaceutical substances and for allowing the pharmaceutical substances to permeate the blood-brain barrier, the pharmaceutical substances having at least one or more amidine, guanidine, N-hydroxyamidine (amidoxime) or N-hydroxyguanidine functions. The invention also relates to medicaments containing the correspondingly modified pharmaceutical substances.
• US9353047B2
  申请人：——

  公开号：US9353047B2

  公开（公告）日：2016-05-31
• The Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the Activation of <i>N</i>-Hydroxylated Prodrugs
  作者：Sanja Gruenewald、Bettina Wahl、Florian Bittner、Helen Hungeling、Stephanie Kanzow、Joscha Kotthaus、Ulrike Schwering、Ralf R. Mendel、Bernd Clement

  DOI：10.1021/jm8010417

  日期：2008.12.25

  The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b(5) and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.